New cancer biology findings pinpoint KMT2C/D loss as a targetable weakness by linking the alteration to downstream dependencies in tumor growth. The study frames KMT2C/D as part of broader epigenetic regulation through the COMPASS complex (Complex of Proteins Associated with Set1), which controls differentiation and cell identity programs. By mapping how loss of these epigenetic regulators reshapes the tumor state, the researchers argue it creates exploitable vulnerabilities—an angle that may support future combination strategies, especially in settings where current targeted therapies struggle. For translational teams, the key development is a mechanistic rationale that can inform biomarker selection and therapeutic target prioritization.